CAR-T therapies are highly promising but require patient-by-patient
engineering that delays treatment and increases cost to a point that
could limit adoption in the current healthcare economy. For CAR-T
therapies to remain viable, it is necessary to: (i) reduce costs of
autologous therapies; and (ii) develop new allogeneic ‘off-the-shelf’
therapies.

In off-the-shelf therapies, allogeneic cells sourced from healthy donors
undergo industrial-scale engineering and production in a centralized
facility, producing a ready-to-ship product that requires minimal
preparation before infusion, making broad distribution possible.